A computational study of non-coding RNAs on the regulation of activating transcription factor 3 in human breast cancer cells

被引:10
|
作者
Akshaya, R. L. [1 ]
Akshaya, N. [1 ]
Selvamurugan, N. [1 ]
机构
[1] SRM Inst Sci & Technol, Coll Engn & Technol, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India
关键词
Breast cancer; ATF3; miRNA; lncRNA; circRNA; EPITHELIAL-MESENCHYMAL TRANSITION; GENE-REGULATION; EXPRESSION; ATF3; PREDICTION; DATABASE; SPONGE; CERNA;
D O I
10.1016/j.compbiolchem.2020.107386
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We previously reported that activating transcription factor 3 (ATF3), an adaptive response gene, plays a dichotomous role in regulating several molecular processes during breast cancer progression. ATF3 promoted the expression of runt-related transcription factor 2 (Runx2, a metastatic gene) and activated matrix metalloproteinase 13 (MMP13, an invasive gene), thereby fostering proliferation and bone-metastasis of the breast cancer cells. Targeting ATF3 may mitigate the metastatic spread of breast cancer and improve the patient's lifespan. Non-coding RNAs (ncRNAs) such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) are the new-era regimens that are currently utilized for diagnosis and treatment of a variety of malignancies including cancer. mir-3674 putatively targets ATF3, but its expression was significantly increased in human breast cancer cells (MDA-MB231), compared to normal human mammary epithelial cells (MCF-10A). Our in silico analysis identified a few lncRNAs and circRNAs showing their putative binding sites for miR-3674. Thus, mir-3674, despite its abundance in the MDA-MB231 cells, could not effectively target ATF3, which could be due to the sponging mechanism of lncRNAs and circRNAs towards mir-3674. More extensive in vitro and in vivo studies are required to validate this and expand the diagnostic and therapeutic perspectives of breast cancer.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Cancer fusion transcripts with human non-coding RNAs
    Mohammad, Tharaa
    Zolotovskaia, Marianna A.
    Suntsova, Maria V.
    Buzdin, Anton A.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [32] Long Non-Coding RNAs, Cell Cycle, and Human Breast Cancer
    Yin, Qinan
    Ma, Haodi
    Bamunuarachchi, Gayan
    Zheng, Xuewei
    Ma, Yan
    HUMAN GENE THERAPY, 2023, 34 (11-12) : 481 - 494
  • [33] Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications
    Benacka, Roman
    Szaboova, Daniela
    Gulasova, Zuzana
    Hertelyova, Zdenka
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (01)
  • [34] Long Non-Coding RNAs in Drug Resistance of Breast Cancer
    Du, Tonghua
    Shi, Ying
    Xu, Shengnan
    Wan, Xiaoyu
    Sun, Haiyin
    Liu, Bin
    ONCOTARGETS AND THERAPY, 2020, 13 : 7075 - 7087
  • [35] Editorial: Non-coding RNAs in breast cancer, volume II
    Zhang, Wenwen
    Kataoka, Naoyuki
    Guan, Xiaoxiang
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [36] Non-Coding RNAs as Regulators of Mammary Development and Breast Cancer
    Piao, Hai-long
    Ma, Li
    JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2012, 17 (01) : 33 - 42
  • [37] Non-Coding RNAs as Regulators of Mammary Development and Breast Cancer
    Hai-long Piao
    Li Ma
    Journal of Mammary Gland Biology and Neoplasia, 2012, 17 : 33 - 42
  • [38] Unraveling non-coding RNAs in breast cancer: mechanistic insights and therapeutic potential
    Shaikh, Muqtada
    Doshi, Gaurav
    MEDICAL ONCOLOGY, 2024, 42 (01)
  • [39] The regulatory roles of long non-coding RNAs in the development of chemoresistance in breast cancer
    Malhotra, Akshay
    Jain, Manju
    Prakash, Hridayesh
    Vasquez, Karen M.
    Jain, Aklank
    ONCOTARGET, 2017, 8 (66) : 110671 - 110684
  • [40] Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes
    Su, Xiaoping
    Malouf, Gabriel G.
    Chen, Yunxin
    Zhang, Jianping
    Yao, Hui
    Valero, Vicente
    Weinstein, John N.
    Spano, Jean-Philippe
    Meric-Bernstam, Funda
    Khayat, David
    Esteva, Francisco J.
    ONCOTARGET, 2014, 5 (20) : 9864 - 9876